Rapid Micro Biosystems (RPID)
(Delayed Data from NSDQ)
$0.93 USD
-0.05 (-5.48%)
Updated May 1, 2024 03:59 PM ET
After-Market: $0.93 0.00 (-0.01%) 4:40 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Balance Sheet
Fiscal Year End for Rapid Micro Biosystems, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 92 | 109 | 194 | 45 | 12 |
Receivables | 6 | 5 | 5 | 5 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 20 | 21 | 16 | 9 | 6 |
Other Current Assets | 3 | 3 | 4 | 3 | 2 |
Total Current Assets | 120 | 139 | 218 | 62 | 24 |
Net Property & Equipment | 13 | 14 | 11 | 7 | 8 |
Investments & Advances | 3 | 30 | 10 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 1 | 0 |
Total Assets | 143 | 191 | 241 | 70 | 32 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 4 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 8 | 11 | 7 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 5 | 3 | 4 | 2 |
Total Current Liabilities | 19 | 19 | 18 | 16 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 25 | 18 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 2 | 153 | 83 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 4 | 3 |
Total Liabilities | 25 | 26 | 20 | 197 | 114 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 546 | 541 | 536 | 115 | 122 |
Retained Earnings | -428 | -376 | -315 | -242 | -205 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 118 | 164 | 221 | -127 | -83 |
Total Liabilities & Shareholder's Equity | 143 | 191 | 241 | 70 | 32 |
Total Common Equity | 118 | 164 | 221 | -127 | -83 |
Shares Outstanding | 42.40 | 42.00 | 41.40 | NA | NA |
Book Value Per Share | 2.78 | 3.91 | 5.34 | 0.00 | 0.00 |
Fiscal Year End for Rapid Micro Biosystems, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 92 | 89 | 106 | 100 |
Receivables | NA | 6 | 4 | 3 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 20 | 20 | 21 | 21 |
Other Current Assets | NA | 3 | 2 | 2 | 3 |
Total Current Assets | NA | 120 | 115 | 133 | 129 |
Net Property & Equipment | NA | 13 | 13 | 13 | 14 |
Investments & Advances | NA | 3 | 15 | 7 | 22 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 143 | 150 | 161 | 173 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 7 | 8 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 5 | 5 | 6 |
Total Current Liabilities | NA | 19 | 16 | 14 | 14 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 22 | 21 | 21 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 546 | 545 | 544 | 542 |
Retained Earnings | NA | -428 | -417 | -404 | -390 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 118 | 128 | 140 | 152 |
Total Liabilities & Shareholder's Equity | NA | 143 | 150 | 161 | 173 |
Total Common Equity | 0 | 118 | 128 | 140 | 152 |
Shares Outstanding | 42.50 | 42.40 | 42.40 | 42.30 | 42.30 |
Book Value Per Share | 0.00 | 2.78 | 3.01 | 3.30 | 3.60 |